GlassScriptPhysician profile
Aaron T Ludwig
NPI 1386956019
$2,237.48
in general payments reported to CMS, 2019-2025
31 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $138 · 2021: $222 · 2022: $184 · 2023: $201 · 2024: $710 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $281.46 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $235.06 | 2023-2025 | Orgovyx, Gemtesa |
| Becton, Dickinson and Company | $225.35 | 2023-2024 | Bard Urinary Drainage Bag |
| Pfizer INC. | $175.44 | 2019-2025 | |
| Janssen Biotech, INC. | $140.44 | 2019-2024 | Erleada |
| Merck Sharp & Dohme LLC | $136.11 | 2020-2025 | Keytruda, Welireg |
| C. R. Bard, INC. & Subsidiaries | $128.41 | 2024-2025 | Bard Urinary Drainage Bag |
| Genzyme Corporation | $99.24 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $74.72 | 2019-2021 | |
| Myovant Sciences INC. | $62.52 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $58.28 | 2019-2020 | |
| Antares Pharma, INC. | $56.28 | 2019-2022 | |
| Accord Healthcare, INC. | $49.29 | 2024 | |
| Myriad Genetic Laboratories, INC. | $48.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.90 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.99 | 2020-2024 | |
| Amgen INC. | $42.72 | 2019-2020 | |
| Calyxo, INC. | $40.68 | 2025 | Cvac Aspiration System |
| Progenics Pharmaceuticals, INC. | $37.79 | 2023-2024 | Pylarify |
| Coloplast Corp | $35.73 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $28.87 | 2019-2020 | |
| Clarus Therapeutics INC. | $27.76 | 2021 | |
| Conmed Corporation | $26.88 | 2024 | Airseal |
| Blue Earth Diagnostics | $26.29 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $19.19 | 2025 | |
| Cycle Pharmaceuticals INC | $17.78 | 2025 | Venxxiva |
| Astrazeneca Pharmaceuticals LP | $17.76 | 2024 | Lynparza |
| Immunitybio, INC. | $17.45 | 2024 | |
| Urogen Pharma, INC. | $16.61 | 2025 | |
| Abbvie INC. | $12.15 | 2019 | |
| Zyla Life Sciences, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ludwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.